Nicole Germino
Stock Analyst at Truist Securities
(1.90)
# 2,948
Out of 4,829 analysts
22
Total ratings
36.84%
Success rate
-4.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nicole Germino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $21 → $10 | $2.35 | +325.53% | 2 | Apr 7, 2025 | |
| YMAB Y-mAbs Therapeutics | Maintains: Buy | $21 → $18 | $3.89 | +362.72% | 2 | Mar 5, 2025 | |
| INSM Insmed | Maintains: Buy | $105 → $108 | $65.08 | +65.95% | 8 | Feb 21, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $5 | $0.70 | +614.08% | 5 | Jan 23, 2025 | |
| ASMB Assembly Biosciences | Downgrades: Hold | $132 → $24 | $12.24 | +96.08% | 3 | Oct 24, 2022 | |
| FBRX Forte Biosciences | Downgrades: Hold | n/a | $6.29 | - | 2 | Sep 3, 2021 |
Perspective Therapeutics
Apr 7, 2025
Maintains: Buy
Price Target: $21 → $10
Current: $2.35
Upside: +325.53%
Y-mAbs Therapeutics
Mar 5, 2025
Maintains: Buy
Price Target: $21 → $18
Current: $3.89
Upside: +362.72%
Insmed
Feb 21, 2025
Maintains: Buy
Price Target: $105 → $108
Current: $65.08
Upside: +65.95%
Sangamo Therapeutics
Jan 23, 2025
Maintains: Buy
Price Target: $7 → $5
Current: $0.70
Upside: +614.08%
Assembly Biosciences
Oct 24, 2022
Downgrades: Hold
Price Target: $132 → $24
Current: $12.24
Upside: +96.08%
Forte Biosciences
Sep 3, 2021
Downgrades: Hold
Price Target: n/a
Current: $6.29
Upside: -